<span item_type="fundamental" item_id="f52330abf164d80a13169c59e71d4c00" counter_id="ST/US/JSPRW" env="prod"></span><span item_type="announcement" item_id="549078453283855233" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD -1.74.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Research and Development Expenses</strong>: Increased by $9.9 million from $11.3 million for the three months ended June 30, 2024, to $21.2 million for the three months ended June 30, 2025, primarily due to increased program costs and personnel-related expenses.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Net Loss</strong>: The company reported a net loss of $26.7 million for the three months ended June 30, 2025, compared to a net loss of $14.6 million for the same period in 2024, representing an increase of 83%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li><li><strong>General and Administrative Expenses</strong>: Increased by $1.2 million from $4.7 million for the three months ended June 30, 2024, to $5.9 million for the three months ended June 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: $38.3 million for the six months ended June 30, 2025, compared to $27.4 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $6.2 million for the six months ended June 30, 2025, primarily from the issuance and sale of shares of common stock under the ATM Offering.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Program Costs</strong>: Increased by $9.6 million from $6.2 million for the three months ended June 30, 2024, to $15.8 million for the three months ended June 30, 2025, driven by increased costs for the CSU program and the initiation of the asthma program.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company plans to focus on its briquilimab clinical development programs in chronic urticaria and has halted enrollment in its Phase 1b/2a asthma study and other clinical and preclinical programs to extend its cash runway.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li><li><strong>Non-Core Business</strong>: The SCID program and any remaining Investigator Sponsored Trials (ISTs) are being discontinued to focus resources exclusively on mast cell disease development programs.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li><li><strong>Priority</strong>: The company intends to become a fully integrated discovery, development, and commercial company in the field of mast cell therapeutics, with plans to advance product candidates through regulatory approval and commercialization.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1788028/000121390025075635/ea0252091-10q_jasper.htm"></span></li></ul>

Jasper Therapeutics - CW26 | 10-Q: FY2025 Q2 EPS: USD -1.74